L-Asparaginaz, Omacetaxine, Hidroksiüre ve Enhancer of Zeste Homolog 2 (EZH-2) İnhibitörleri
Özet
Bu makale, hematolojik malignitelerin tedavisinde kritik öneme sahip antineoplastik ilaçlar olan L-asparaginaz, Omacetaxine, Hidroksiüre ve EZH-2 inhibitörlerinin etki mekanizmalarını, klinik kullanım alanlarını ve yan etki profillerini kapsamlı bir şekilde incelemektedir. Escherichia coli kökenli bir polipeptit olan L-asparaginaz, kanda serbest dolaşan L-asparajini tüketerek asparajin sentetaz enzimi eksik olan lösemik hücrelerin protein sentezini engeller ve özellikle akut lenfoblastik lösemi (ALL) protokollerinde başarıyı önemli ölçüde artırır. Tirozin kinaz inhibitörlerine dirençli kronik myeloid lösemi (KML) hastaları için onaylanan Omacetaxine, ribozomların A bölgesine bağlanarak protein biyosentezini tümüyle inhibe eder ve Bcr-Abl gibi kısa ömürlü proteinleri azaltarak hücre ölümünü tetikler. Bir antimetabolit olan Hidroksiüre, ribonükleozid difosfat redüktazı seçici olarak inhibe ederek hücre döngüsünü G1/S fazında durdurur; bu etkisiyle miyeloproliferatif hastalıkların yanı sıra fetal hemoglobin düzeyini artırarak orak hücreli aneminin tedavisinde de etkin bir şekilde kullanılır. Son olarak, epigenetik değişiklikleri hedefleyen Tazemetostat gibi yeni nesil EZH-2 inhibitörleri, polikomb baskılayıcı kompleks 2'nin (PRC2) enzimatik alt birimini baskılayarak gen ekspresyonunu düzenler ve özellikle mutasyon pozitif nükseden veya dirençli foliküler lenfoma ile epitelioid sarkom tedavisinde umut verici klinik başarılar sunar. İlaçların kemik iliği baskılanması, aşırı duyarlılık ve kutanöz toksisite gibi ciddi yan etkileri yakın klinik takip gerektirmektedir.
This article comprehensively examines the mechanism of action, clinical indications, and side effect profiles of L-asparaginase, Omacetaxine, Hydroxyurea, and EZH-2 inhibitors, which are critical antineoplastic drugs in the treatment of hematologic malignancies. L-asparaginase, a polypeptide derived from Escherichia coli, depletes free-circulating L-asparagine in the blood, thereby inhibiting protein synthesis in leukemic cells that lack the asparagine synthetase enzyme, which significantly increases the success rates in acute lymphoblastic leukemia (ALL) protocols. Approved for chronic myeloid leukemia (CML) patients resistant to tyrosine kinase inhibitors, Omacetaxine binds to the A-site cleft of ribosomes to inhibit total protein biosynthesis, leading to the reduction of short-lived proteins like Bcr-Abl and subsequent cell death. Hydroxyurea, an antimetabolite, selectively inhibits ribonucleoside diphosphate reductase, arresting the cell cycle at the G1/S phase; through this mechanism, it is effectively utilized in myeloproliferative diseases and sickle cell anemia by increasing fetal hemoglobin levels. Lastly, next-generation EZH-2 inhibitors, such as Tazemetostat, target epigenetic alterations by suppressing the enzymatic subunit of polycomb repressive complex 2 (PRC2) to regulate gene expression, offering promising clinical efficacy in relapsed or refractory follicular lymphoma and epithelioid sarcoma. The severe adverse effects of these agents, including bone marrow suppression, hypersensitivity, and cutaneous toxicities, necessitate stringent clinical monitoring.
Referanslar
Saadet Akarsu, Erdal Yılmaz, A. Denizmen Aygün, Sevgi Gözdaşoğlu4. Akut lenfoblastik lösemili çocuklarda L-asparajinaz tedavisi ve komplikasyonları. Türk Pediatri Arşivi. 2004; 39: 162- 170.
Ali Bay, Ahmet Faik Öner, Yaşar Cesur, Cengiz Demir, Yurdagül Mukul, Mehmet Açıkgöz. Çocukluk Çağı Akut Lenfoblastik Lösemi Olgularında L-Asparajinaz’a Bağlı Toksisite. Van Tıp Dergisi. 2005; 12 (2):149-152.
Tahira Batool & Essam A. Makky & Muna Jalal & Mashitah M. Yusoff. A Comprehensive Review on L-Asparaginase and Its Applications. Appl Biochem Biotechnol. 2016; 178:900–923.
Verma, N., Bansal, M., & Kumar, S. (2012).Whole cell based miniaturized fiber optic biosensor to monitör L-asparagine. Journal of Applied Sciences Research, 3, 809–814.
Subhash Chand, Richi V. Mahajan, Jai Prakash Prasad, Debendra K. Sahoo, Kanti Nandan Mihooliya, Mahesh S. Dhar, Girish Sharma. A comprehensive review on microbial L-asparaginase: Bioprocessing, characterization, and industrial applications. International Union of Biochemistry and Molecular Biology. 2020; p: 1–29.
Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol 2014; 32:3874.
Otten J, Philippe N, Suciu S, et al. The children leukemias group, 30 years of research and achievements. Eur J Cancer. 2002; 38: 44- 49.
Silverman LB, Levy DE, Dalton VK, et al. Erwinia L-asparaginase is less toxic and less effective than E. coli L-asparaginase in Proc Am Soc Clin Oncol 2002; 21: 389.
Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia. Oncologist 2007; 12:991.
HemOnc.org - A Hematology Oncology Wiki 2022. (05/10/2022 tarihinde (https://hemonc.org/wiki/B-cell acute lymphoblastic leukemia adresinden ulaşılmıştır).
Salzer,W. L., Asselin, B. L., Plourde, P. V., Corn, T., & Hunger, S. P.Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia. Annals of the New York Academy of Sciences, 2014; 1329: 81–92.
Vrooman LM et al. Activity and toxicity of intravenous Erwinia asparaginase following allergy to E. Coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia. Pediatr Blood Cancer 2016; 63(2):228–233.
Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12:601.
Petersen WC Jr, Clark D, Senn SL, et al. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2014; 31:311.
Liu Y, Smith CA, Panetta JC, et al. Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. J Clin Oncol 2019; 37:2051.
Cooper SL, Young DJ, Bowen CJ, et al. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer 2019; 66:e27797.
Gurel G, Blaha G, Moore PB, Steitz TA. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol. 2009; 389:146–56.
Varsha Gandhi, William Plunkett, and Jorge E. Cortes. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemias. Clin Cancer Res. 2014; 20(7): 1735–1740.
Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012; 120:2573.
Cortes J, Digumarti R, Parikh PM, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol 2013; 88:350.
Cortes JE, Kantarjian HM, Rea D, et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer 2015; 121:1637.
Wellstein A, Giaccone G, Atkins MB, Sausville EA. Hydroxyurea. Cytotoxic drugs. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1195-1196.
Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell Disease. Ann Intern Med. 2008;148(12):932-938.
Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057-1069.
Rodgers GP, Dover GJ, Uyesaka N, et al. Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease. N Engl J Med. 1993;328(2):73-80.
Ferster A, Tahriri P, Vermylen C, et al. Five Years of Experience With Hydroxyurea in Children and Young Adults With Sickle Cell Disease. Blood. 2001;97(11):3628-3632.
Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol. 2012;87(5):552-554.
Worley B, Glassman SJ. Acral keratoses and leucocytoclastic vasculitis occurring during treatment of essential thrombocythaemia with hydroxyurea. Clin Exp Dermatol. 2016;41(2):166-169.
Mattessich S, Ferenczi K, Lu J. Successful treatment of hydroxyurea-associated panniculitis and vasculitis with low-dose methotrexate. JAAD Case Rep. 2017;3(5):422-424.
Rose PG, Ali S, Watkins E, et al. Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(19):2804-2810.
Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121.
Sahoo LK, Kullu BK, Patel S, et al. Study of seminal fluid parameters and fertility of male sickle cell disease patients and potential impact of hydroxyurea treatment. J Assoc Physicians India. 2017;65(6):22-25.
Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
Joseph L, Jean C, Manceau S, et al. Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease. Blood. 2021;137(6):826-829.
Berman E, Druker BJ, Burwick R. Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy. J Clin Oncol. 2018;36(12):1250-1256.
Montironi R, Cupaiolo R, Kadji C, et al. Management of sickle cell disease during pregnancy: experience in a third-level hospital and future recommendations. J Matern Fetal Neonatal Med. 2020:1-9.
Ware RE, Marahatta A, Ware JL, McElhinney K, Dong M, Vinks AA. Hydroxyurea exposure in lactation: a pharmacokinetics study (HELPS). J Pediatr. 2020;222:236-239.
Ran Duan, Wenfang Du and Weijian Guo. EZH2: a novel target for cancer treatment. Journal of hematology and oncology 2020. 28;13(1):104.
Jennifer K. Lue, Jennifer E. Amengual. Emerging EZH2 Inhibitors and Their Application in Lymphoma. Current Hematologic Malignancy Reports. 2018;13:369–382.
Edith Julia, Gilles Salles. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. Future Oncol. 2021;17(17):2127-2140.
Sheridan M Hoy. Tazemetostat: First Approval. Drugs 2020. 80(5):513-521.
